UMC Utrecht

Running trials

• Not yet recruiting

  The CORE Platform Trial

  NCT07892976· Source

• Not yet recruiting

  The HYCORE1 Trial: Hybrid Revascularization Versus Coronary Artery Bypass Grafting

  NCT05504031· Source

• Recruiting

  Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

  NCT07645625· Phase 4· Source

• Recruiting

  Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

  NCT07000253· Phase 2· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Source

• Enrolling by invitation

  Coronary Sinus Reducer in Coronary Microvascular Disease

  NCT06898541· Source

• Recruiting

  Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

  NCT07100730· Phase 3· Source

• Recruiting

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Source

• Not yet recruiting

  Wearables and Artificial Intelligence in Advanced Heart Failure Care

  NCT07051356· Source

• Recruiting

  Towards Cure Via Only Ultra-short ICB in CSCC

  NCT06823479· Phase 2· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Recruiting

  Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI

  NCT07121842· Source

• Recruiting

  Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

  NCT06526195· Source

• Recruiting

  Artificial Intelligence in ANOCA

  NCT06387693· Source

• Recruiting

  The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma

  NCT06355427· Phase 2/3· Source

• Enrolling by invitation

  Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm

  NCT06432452· Phase 2/3· Source

• Active, not recruiting

  HOPE at Heart (HOPE) of Donor Hearts After Circulatory Death (DCD) Using the XVIVO Heart Assist Transport System.

  NCT06485596· Source

• Not yet recruiting

  FET-PET-Guided Management of Pseudoprogression in Glioblastoma

  NCT06480721· Source

• Recruiting

  FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer

  NCT06563986· Phase 2· Source

• Recruiting

  Hand Function Impairment in Systemic Sclerosis: Outcomes, Mechanisms and Experience (HANDSOME)

  NCT06133244· Source

• Recruiting

  The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

  NCT06082492· Source

• Active, not recruiting

  A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

  NCT06260709· Phase 2· Source

• Recruiting

  The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)

  NCT06138223· Source

• Active, not recruiting

  VOLT CE Mark Study

  NCT06106594· Source

• Recruiting

  Percutaneous Peritoneal Dialysis Catheter Insertion (PREDICT)

  NCT06065982· Source

• Active, not recruiting

  Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

  NCT05817942· Source

• Recruiting

  MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible (MARGARITA)

  NCT05937958· Source

• Recruiting

  National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

  NCT05326620· Source

• Active, not recruiting

  Synthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case

  NCT06794281· Source

• Active, not recruiting

  Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients

  NCT05037461· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Source

• Active, not recruiting

  Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· Phase 1/2· Source

• Recruiting

  Safety and Cost-efficiëncy of New Imaging Techniques in Patients Suspected of Coronary Artery Disease

  NCT04939207· Source

• Recruiting

  Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

  NCT05463757· Source

• Active, not recruiting

  Percutaneous Coronary Intervention Before Transcatheter Aortic Valve Implantation

  NCT05078619· Source

• Active, not recruiting

  The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas Patients

  NCT05741944· Source

• Active, not recruiting

  The SELUTION DeNovo Study

  NCT04859985· Source

• Active, not recruiting

  A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

  NCT04825743· Phase 3· Source

• Active, not recruiting

  Image Supported Lead Placement in CRT

  NCT05053568· Source

• Active, not recruiting

  Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

  NCT04663347· Phase 1/2· Source

• Recruiting

  Distress In CErvical Cancer Patients and Partners

  NCT04475354· Source

• Enrolling by invitation

  The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)

  NCT06083155· Source

• Active, not recruiting

  SELUTION SLR™ 014 In-stent Restenosis

  NCT04280029· Source

• Recruiting

  Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial

  NCT06434896· Source

• Active, not recruiting

  Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

  NCT03425838· Phase 3· Source

• Active, not recruiting

  Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

  NCT02811861· Phase 3· Source

• Active, not recruiting

  REDUCER-I: An Observational Study of the Neovasc Reducer™ System

  NCT02710435· Source

• Recruiting

  Cerebellar Mutism Syndrome Study

  NCT02300766· Source

• Recruiting

  Prospective Data Collection Initiative on Colorectal Cancer

  NCT02070146· Source

• Active, not recruiting

  Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)

  NCT01385176· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease7 recruiting
• Cervical cancer3 recruiting
• Colorectal cancer3 recruiting
• Gastric and esophageal cancer3 recruiting
• Glioblastoma3 recruiting
• Childhood cancers2 recruiting
• Heart failure2 recruiting
• Lung cancer2 recruiting
• ALS (motor neurone disease)1 recruiting
• Chronic kidney disease1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mesothelioma1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

  NCT06468527· Phase 2· Source

• Terminated

  Baroloop Multicenter Trial (Baroloop MCT)

  NCT06518915· Source

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Source

• Completed

  Dual Hormone Closed Loop in Type 1 Diabetes

  NCT05669547· Source

• Completed

  Fluorescence Imaging of the Parathyroid Glands of Children

  NCT05917067· Source

• Completed

  Assessment of Digital Consultations on Clinical Impact and Efficiency

  NCT05413447· Source

• Terminated

  Radioembolization in Elderly/ Fragile Patients With mCRC

  NCT05092880· Phase 2· Source

• Completed

  A Study of Surgical Interventions in Fistulizing Conditions

  NCT04940611· Source

• Completed

  Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

  NCT04437303· Phase 4· Source

• Terminated

  A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

  NCT04494256· Phase 1/2· Source

• Completed

  Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

  NCT04340076· Phase 4· Source

• Completed

  Study of DF1001 in Patients With Advanced Solid Tumors

  NCT04143711· Phase 1/2· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Source

• Completed

  Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

  NCT03184194· Phase 2· Source

• Completed

  Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy

  NCT03387761· Phase 1· Source

• Completed

  Experiences and Health-related Quality of Life of Informal Caregivers of Dialysis Patients

  NCT05646615· Source

• Completed

  Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· Phase 3· Source